A unit is not a dose, and it never was
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
Patient Notes in 2025
Page 4 of 11 of this archive, newest first.
What STEP 4 and SURMOUNT-4 actually established
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
India pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Australia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
Discontinuation rates, read honestly
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Canada pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
Portugal pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What STEP 4 and SURMOUNT-4 actually established
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
What the new Switzerland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Four millimetres is enough, and the data says so
The insulin injection-technique literature is large, well conducted and directly transferable on questions of depth and tissue. We say where it stops transferring.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Norway pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The one randomised trial that combined an incretin with supervised exercise
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
Rapid weight loss moves eight analytes for reasons that have nothing to do with the drug
Three different explanations for the same abnormal number, and how to tell them apart.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Priming a pen is not optional
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…